Table 2 Clinical characteristics of HBoV-positive and HBoV-negative patients
Variable | HBoV-positive (n = 88) | HBoV-negative (n = 790) | X2/Z | P |
|---|---|---|---|---|
Gender | 1.796 | 0.180 | ||
Male | 57 (64.8%) | 453 (57.3%) | ||
Female | 31 (35.2%) | 337 (42.7%) | ||
Age | 6.059 | 0.048* | ||
< 2 | 56 (63.6%) | 406 (51.4%) | ||
2–5 | 26 (29.5%) | 271 (34.3%) | ||
≧ 5 | 6 (6.8%) | 113 (14.3%) | ||
Clinical features | ||||
Cough | 85 (96.6%) | 759 (96.1%) | 0.056 | 1.000 |
Wheezing | 25 (28.4%) | 140 (17.7%) | 5.926 | 0.015* |
Tachypnea | 15 (17.0%) | 71 (9.0%) | 5.819 | 0.016* |
Pharyngeal hyperaemia | 65 (73.9%) | 613 (77.6%) | 0.627 | 0.429 |
Rales | 30 (34.1%) | 214 (27.1%) | 1.935 | 0.164 |
Fever | 58 (65.9%) | 506 (64.1%) | 0.119 | 0.730 |
WBC, 109/L | 9.2 (6.9, 11.5) | 8.5 (6.8, 10.8) | − 1.302 | 0.193 |
HGB, g/L | 128.0 (116.0, 137.0) | 127.0 (118.0, 137.0) | − 0.012 | 0.990 |
LDH, U/L | 306.5 (271.8, 344.3) | 291.0 (254.5, 335.0) | − 2.231 | 0.026* |
AST, U/L | 34.6 (28.0, 39.0) | 32.2 (25.6, 39.1) | − 1.384 | 0.178 |
ALT, U/L | 13.9 (9.9, 20.1) | 14.1 (10.1, 21.9) | − 0.558 | 0.577 |
Hospitalization days | 7.0 (5.0, 8.8) | 6.0 (5.0, 8.0) | − 0.770 | 0.441 |
Severe pneumonia | 10 (11.4%) | 39 (4.9%) | 6.207 | 0.023* |